Issue 44
To successfully develop and market a drug product, bio/pharmaceutical companies must adhere to strict regulations and guidelines, which have been set out to ensure quality, efficacy, and safety…
Issue 43
Pharmaceutical packaging solution providers need to consider a host of factors when developing potential solutions for the costly drug products to be housed within. Not only must packaging…
Issue 42
The global biopharmaceutical industry has been experiencing a period of significant growth over recent years, with biologic-based drugs comprising an expanding share of the market...
Issue 41
Biologic-based therapeutics are increasingly in demand, thanks to their ability to provide more targeted and personalized treatment options for a variety of chronic and difficult-to-treat conditions…
Issue 40
Formulating a drug product is one of the most important parts of development and can determine whether or not a company will be triumphant when they seek commercialization...
Issue 39
Oral delivery is still the preferred route of administration for most approved, commercially available products. Thanks to the popularity of the dosage form, demand for oral solid drugs,…
Issue 38
So far, 2025 has been financially challenging for the biopharmaceutical and biotech sectors — with limited access to capital and lean financing on offer — further complicated by…
BIO
Marking a highlight of the year for the biotechnology industry, the BIO International Convention will convene once again in Boston, Mass., and is set to offer visitors four…
Issue 37
Novel therapeutic modalities, such as cell, gene, and nucleic acid therapies, are offering more effective, personalized treatment options to patients with chronic and/or rare diseases that were, not…
Issue 36
CPHI Americas has wrapped for 2025, closing its doors at noon (EST) on May 22 after having welcomed over 3,925 attendees and 370 exhibitors, as well as 16…
CPHI Americas
As the month of May marches on, the city of Philadelphia prepares itself to once again play host to CPHI — this year under its new guise of…
Issue 35
Glucagon-like peptide-1 (GLP-1) receptor agonists first penetrated the market 20 years ago when exenatide (Byetta, originally developed by Amylin Pharmaceuticals and Eli Lilly) gained regulatory approval as a…
